The Overweight rating suggests that Cantor Fitzgerald still has a positive outlook on PTC Therapeutics, implying potential outperformance in the market. However, the reduction in the price target may reflect a tempered expectation for the stock's future price appreciation. This could lead to a neutral short-term impact as the market digests the mixed signals of continued confidence in the stock's performance against a lower price target.